Novel triterpene derivatives as HIV inhibitors.
Novel triterpene derivatives address the limitations of current HIV treatments by inhibiting HIV replication through unique mechanisms, offering promising therapeutic options for HIV-mediated diseases.
Patent Information
- Application Number
- JP2021546849
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-02-11
- Filing Date
- 2020-02-11
- Publication Date
- 2025-03-18
- Estimated Expiration
- 2040-02-11
AI Technical Summary
Current treatments for HIV-mediated diseases, particularly those involving HIV maturation inhibitors like bevirimat, have shown limited efficacy due to the development of Gag polymorphisms, leading to non-responsive subjects despite optimal plasma concentrations.
Development of novel triterpene derivatives and related compounds, specifically compounds of formula (I), which are designed to inhibit HIV replication through novel mechanisms of action, potentially overcoming the limitations of existing HIV maturation inhibitors.
The novel triterpene derivatives demonstrate potential as effective anti-HIV agents, capable of inhibiting HIV replication and potentially offering improved therapeutic outcomes compared to existing treatments by targeting different mechanisms.